Paper on Drug Costs From American College of Physicians Ignores Economic Reality

Posted by Ed Schoonveld on Wed, Apr 06, 2016

Providing a view of the issue of rising drug costs, plus specific positions and recommendations for government action, the American College of Physicians (ACP) published a position paper on March 29, 2016, titled “Stemming the Escalating Cost of Prescription Drugs: A Position Paper of the College of the American College of Physicians.”


>
Read More

Re-Pricing Rules in Japan Slash Prices for “Huge Sales” Drugs

Posted by Ed Schoonveld on Mon, Feb 01, 2016

At a recent meeting of the Japanese Central Social Insurance Medical Council (Chuikyo), substantial price cuts for drugs with “huge sales” were discussed. These cuts are to be implemented in April and will impact four brands:


>
Read More

Clinton on Drug-Pricing Warpath: Populism, Real Problem or Both?

Posted by Ed Schoonveld on Mon, Jan 11, 2016

When pointing a finger at someone, usually three fingers are pointed at yourself. U.S. government and presidential candidates should consider this before they rush to the media briefing rooms.


>
Read More

Drug Pricing Discussions at the Forbes Healthcare Summit

Posted by Ed Schoonveld on Wed, Dec 09, 2015

Drug pricing received significant attention at this year’s Forbes Healthcare Summit, held Dec. 2 and 3 in New York. The impressive conference lineup of Merck’s Ken Frazier, Pfizer’s Ian Read, GSK’s Sir Andrew Witty, Celgene’s Bob Hugin, Regeneron’s Len Schleifer, Express Scripts’ Steve Miller and Turing brat Martin Shkreli provided a solid basis for debate on drug pricing.


>
Read More

Pharma Survival in a Transforming Global Environment

Posted by Ed Schoonveld on Thu, Nov 19, 2015

The global pharmaceutical environment is under intense pressure, as a perfect storm of scientific innovation, budget pressures and public concerns over drug pricing is developing. The launch of innovative hepatitis C drugs with strong value propositions and high market needs have posed significant budget pressures for payers worldwide. Unfortunately, the drug industry has been substantially weakened, as the very strong arguments of long-term monetary and humanistic cost savings (cirrhosis, liver transplants and hepatic cancer) have not been sufficiently communicated, thus allowing the discussions to focus on short-term cost only.


>
Read More